Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14614740 | 0.92 | CACNA1H (0.53) | DRD2TDP1SIGMAR1CACNA1HEPHX1 | |
| SCHEMBL24619896 | 0.90 | DRD2 (0.54) | DRD2TDP1SIGMAR1MAOAMAOB | |
| SCHEMBL18947871 | 0.87 | DRD2 (0.54) | DRD2TDP1SIGMAR1MEN1GAA | |
| SCHEMBL22699069 | 0.87 | DRD2 (0.54) | DRD2TDP1SIGMAR1MEN1GAA | |
| SCHEMBL25361923 | 0.87 | DRD2 (0.50) | DRD2TDP1SIGMAR1MAOAMAOB | |
| SCHEMBL8254760 | 0.87 | DRD2 (0.64) | DRD2TDP1SIGMAR1MEN1GAA | |
| SCHEMBL7555 | 0.84 | DRD2 (0.49) | DRD2TDP1SIGMAR1MAOAMAOB | |
| SCHEMBL24922242 | 0.84 | DRD2 (0.51) | DRD2TDP1SIGMAR1MAOAMAOB | |
| SCHEMBL22703621 | 0.84 | DRD2 (0.54) | DRD2TDP1SIGMAR1MEN1GAA | |
| SCHEMBL25031746 | 0.83 | DRD2 (0.55) | DRD2TDP1SIGMAR1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12318452-B2 | Degraders of WEE1 kinase | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20220047709-A1 | DEGRADERS OF WEE1 KINASE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-17 | — | — | US | disclosed |
| US-20220047709-A1 | DEGRADERS OF WEE1 KINASE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-17 | — | — | US | disclosed |
| US-10391175-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-08-27 | — | — | US | disclosed |
| US-10259825-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-10259825-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| EP-3421476-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | Melinta Therapeutics, Inc. (US) | 2019-01-02 | — | — | EP | disclosed |
| EP-2488532-B1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-2488532-B1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-2970312-B1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2017-11-15 | — | — | EP | disclosed |
| US-9023843-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| WO-2014164596-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-10-09 | — | — | WO | disclosed |
| EP-2488532-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | Rib-X Pharmaceuticals, Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120202792-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202792-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2011047320-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011047320-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-5561139-A | IMMUNOSUPPRESSANTS; SIDE EFFECT REDUCTION | ABBOTT LABORATORIES (US) | 1996-10-01 | — | — | US | disclosed |
| US-5530120-A | ANALOGS OF ASCOMYCIN AND FK-506 AS IMMUNOSUPPRESSANTS AND-MODULATORS; SIDE EFFECT REDUCTION | ABBOTT LABORATORIES (US) | 1996-06-25 | — | — | US | disclosed |
| WO-1994021634-A1 | SUBSTITUTED ALICYCLIC-ALIPHATIC AMINE-CONTAINING MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391175-B2 | BET bromodomain inhibitors and therapeutic methods using the same | BRD4, BRDT, BRD3 | DRD2 4222/4885TDP1 546/4885SIGMAR1 4451/4885 |
| US-10259825-B2 | Antimicrobial compounds and methods of making and using the same | LPO, MPO, CAT | DRD2 2557/4885TDP1 2413/4885SIGMAR1 3393/4885 |
| US-20220047709-A1 | DEGRADERS OF WEE1 KINASE | WEE1, WEE2, PPME1 | DRD2 4368/4885TDP1 632/4885SIGMAR1 3373/4885 |
| US-12318452-B2 | Degraders of WEE1 kinase | WEE1, WEE2, PPME1 | DRD2 4368/4885TDP1 632/4885SIGMAR1 3373/4885 |
| US-20120202792-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | LPO, MPO, CAT | DRD2 2557/4885TDP1 2413/4885SIGMAR1 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.